Trials, publications and grants since Nov 2024.
Publication
Clinical characteristics of secondary myeloid neoplasms in patients with inflammatory bowel disease.
British journal of haematology, Oct 2026
Publication
Germ line landscape stratification defines distinct molecular and prognostic groups in therapy-related myeloid neoplasms.
Blood advances, Oct 2026
Publication
HMA+VEN triplet regimens for the initial treatment of AML in adults (PRO).
Blood advances, Oct 2026
Publication
Outcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms.
Cancer, Oct 2026
Publication
Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research, Sept 2026
Publication
Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.
Blood advances, Sept 2026
Publication
LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models.
Blood cancer discovery, Sept 2026
Publication
Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.
Cancer, Aug 2026
Publication
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Jul 2026
Publication
Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial.
Blood cancer discovery, Jul 2026
Publication
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.
Leukemia, Jun 2026
Publication
All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Jun 2026
Publication
Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor.
Blood, Jun 2026
Publication
The role of advanced molecular diagnostics in informing targeted therapies for AML.
Human pathology, May 2026
Publication
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.
Cancer, May 2026
Publication
Mutations in isocitrate dehydrogenase portend a poor prognosis in adult patients with acute lymphoblastic leukemia.
Blood advances, May 2026
Publication
Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic Leukemia.
Blood cancer discovery, May 2026
Publication
Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults.
Leukemia, Apr 2026
Publication
Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.
Leukemia, Apr 2026
Publication
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.
Blood cancer journal, Mar 2026
Publication
Immunophenotypic changes following menin inhibition in acute myeloid leukemia.
Leukemia, Mar 2026
Publication
Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms.
Leukemia, Mar 2026
Publication
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.
Blood advances, Feb 2026
Publication
Clinical, genetic, and familial features of POT1 tumor predisposition syndrome.
Cancer, Feb 2026
Publication
Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.
Blood, Feb 2026
Publication
Case series: rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia.
Leukemia & lymphoma, Feb 2026
Publication
Long-Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax-Based Therapies.
American journal of hematology, Jan 2026
Publication
Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine.
American journal of hematology, Jan 2026
Publication
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Leukemia, Jan 2026
Publication
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.
Leukemia, Dec 2025